Abcuro Announces Participation in Upcoming Investor Conferences
Newton, Massachusetts, November 11, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm
Abcuro Announces Participation in Upcoming Investor Conferences
Newton, Massachusetts, August 29, 2024— Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024,
Abcuro Appoints Sarah Boyce to its Board of Directors
Newton, Massachusetts, July 31, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
Newton, Massachusetts, June 25, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the completion of enrollment of the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM). “We continue
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors
Newton, Massachusetts, December 6, 2023— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors. Dr. Pruzanski brings more than 30 years of experience as
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
Newton, Massachusetts, November 13, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as continued development of additional clinical programs Newton, Massachusetts, August 17, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
Company expects to have a Data Safety and Monitoring Board (DSMB) review by the end of this year Newton, Massachusetts, May 31, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
ABC008 potently and selectively depletes highly cytotoxic T cells which attack and destroy muscle tissue in IBM without affecting protective T cell populations Newton, Massachusetts, April 3, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia
Abcuro Appoints Alex Martin as Chief Executive Officer
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer
Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical Officer
Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022
Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells
Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
Newton, Massachusetts, October 19, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
Newton, MA, October 6, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis
Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle biopsies Newton, MA, June 30, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for
Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer
Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline Newton, MA, January 7, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic
Abcuro Granted Orphan Drug Designation for ABC008 for Inclusion Body Myositis
Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that are pathogenic in IBM Newton, MA, June 9, 2020 – Abcuro, Inc., a clinical-stage biotechnology
